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Nephrotic syndrome (NS) is characterized by massive pro-
teinuria, hypoalbuminemia, and hypercholesterolemia. Min-
imal change nephrotic syndrome (MCNS) is the most com-
mon form of NS in children and membranous nephropa-
thy (MN) is more common in adults. Focal segmental
glomerulosclerosis (FSGS) is one of the primary glomerular
disorders in both children and adults which frequently shows
steroid resistance and can progress to end-stage renal failure.
Recently, there have been advances in the fields of patho-
genesis and treatment of various kinds of NS. In this special
issue, several investigators reviewed the recent advances or
presented the experimental works regarding the pathogenesis
and treatment of NS.
The etiopathogenesis of NS is incompletely understood.
To understand the pathogenesis of primary MN, A. Kron-
bichler et al. reviewed the discovery of several antibodies and
genetics which contributed to an increased understanding of
MN, such as antibodies against theM-type phospholipase A2
receptor (PLA2R), several risk alleles related to the PLA2R1
gene, and thrombospondin type 1 domain-containing 7A
(THSD7A) antibodies.
To understand the genetic causes of NS, M. S. Guaragna
et al. reviewed the list of NPHS2mutations reported between
June 2013 and February 2017, with a closer look to muta-
tions occurring in Latin American countries, emphasizing
the importance of implementing the molecular evaluation
of NS. To understand the pathogenesis of NS, P. Zapata-
Benavides et al. measured different expression levels and
protein localization of WT1 in patients with steroid-sensitive
and steroid-resistant NS and investigated its relationshipwith
miR-15a, miR-16-1, and miR-193a, which modulate the WT1
expression in other models.
V. J. Savin et al. provide an overview of the circulat-
ing permeability factors in primary FSGS that have been
implicated in the pathogenesis of the potential recurrence
in renal allografts after kidney transplantation, focusing on
cardiotrophin-like cytokine factor-1 (CLCF-1); they found
and suggested therapies specific to CLCF-1, including poten-
tial use of cytokine receptor-like factor (CRLF-1) and inhibi-
tion of Janus kinase 2.
Regarding the treatment of NS, S. Thalgahagoda et al.
presented their experiences on administering the anticancer
drug, vincristine, in patients with steroid-resistant NS and
suggested that vincristine could be a potential alternative
treatment of steroid-resistant NS patients. Rituximab, a
chimeric B-cell depleting anti-CD20 antibody, has emerged
in the last decade as a treatment option for patients with
primary glomerular diseases and M. Rudnicki introduced
the data on the use of rituximab in membranoprolifer-
ative glomerulonephritis (MPGN), C3 glomerulonephritis
(C3GN), and dense deposit disease (DDD) by reviewing the
published case reports and retrospective case series.
To provide insight into potential new targets for the
treatment of NS from recent basic science publications, E.
Ko¨nigshausen and L. Sellin reviewed recent advances in the
treatment of primary causes of NS (idiopathic MN, MCNS,
and FSGS) since the publication of the KDIGO guidelines
in 2012 and introduced the ongoing RCTs for these diseases
that will provide further information on the effectiveness of
different treatment options for the causative disease.
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Articles published in this special issue covered the various
fields of NS such as pathophysiologic mechanisms and treat-
ment options. Understanding theses various faces of NS will
lead to the better patient treatment and outcome.
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